Product Description
Mechanisms of Action: ET Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Idorsia
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Heart Failure, Acute|Heart Failure, Chronic|Hypertension, Pulmonary|Pulmonary Heart Disease|Neuromyelitis Optica|Heart Failure
Phase 2: Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2009-012450-20 | P2 |
Completed |
Hypertension, Pulmonary |
2011-05-10 |
|
| AC-051-207 | P2 |
Terminated |
Familial Primary Pulmonary Hypertension|Hypertension, Pulmonary |
2010-12-01 |
22% |
| AC-051-206 | P2 |
Terminated |
Familial Primary Pulmonary Hypertension|Hypertension, Pulmonary |
2010-11-01 |
|
| 2006-002907-15 | P3 |
Completed |
Pulmonary Heart Disease|Heart Failure|Neuromyelitis Optica|Hypertension, Pulmonary |
2008-02-08 |